Literature DB >> 3032586

Identification of a corticotropin-releasing factor-binding protein in the plasma membrane of AtT-20 mouse pituitary tumor cells and its regulation by dexamethasone.

B E Rosendale, D B Jarrett, A G Robinson.   

Abstract

CRF stimulates the synthesis and secretion of proopiomelanocortin-derived peptides from AtT-20 mouse pituitary tumor cells. This study has shown that there is a specific binding site for CRF located on the plasma membrane of these cells. Both [125I]iodo-Tyr0CRF and noniodinated CRF (10(-11)-10(-7) M) stimulated, in a dose-dependent manner, the secretion of equimolar amounts of beta-endorphin-like immunoactivity from AtT-20 cells. Disuccinimidyl suberate, a cross-linking agent, was used to demonstrate specific binding of [125I]iodo-Tyr0CRF to plasma membranes from these cells. After cross-linking [125I] iodo-Tyr0CRF, the membrane proteins were solubilized with sodium dodecyl sulfate and electrophoresed on a 10% polyacrylamide gel. A single radioactively labeled band, corresponding to a mol wt of 66,000, was identified by autoradiography. [125I]Iodo-Tyr0CRF binding to these membranes was inhibited by 10(-7) M unlabeled CRF or an equimolar concentration of the CRF analog sauvagine. Similar concentrations (10(-7) M) of TRH, GnRH, insulin, [Arg8]vasopressin, somatostatin, and ACTH did not inhibit [125I]iodo-Tyr0CRF binding to the plasma membranes. Incubation of AtT-20 cells for 24 h in the presence of 10 nM dexamethasone reduced [125I]iodo-Tyr0CRF binding by 80% compared to that in untreated cells. Dexamethasone also inhibited the CRF-stimulated beta-endorphin-like immunoactivity secretory response. These data indicate that binding of CRF to a specific membrane protein is an integral component in the stimulation of AtT-20 cells by CRF.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3032586     DOI: 10.1210/endo-120-6-2357

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

1.  Expression cloning of a human corticotropin-releasing-factor receptor.

Authors:  R Chen; K A Lewis; M H Perrin; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

2.  CRH-stimulation of cyclic adenosine 5'-monophosphate pathway is partially inhibited by the coexpression of CRH-R1 and CRH-R2alpha.

Authors:  G Maya-Núñez; C Castro-Fernández; J P Méndez
Journal:  Endocrine       Date:  2005-06       Impact factor: 3.633

Review 3.  Physiological and neurochemical aspects of corticotropin-releasing factor actions in the brain: the role of the locus coeruleus.

Authors:  H Lehnert; C Schulz; K Dieterich
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

4.  Synthesis and characterization of a photoactivatable analog of corticotropin-releasing factor for specific receptor labeling.

Authors:  A Rühmann; A K Köpke; F M Dautzenberg; J Spiess
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

5.  Vasopressin stimulation of adrenocorticotropin hormone (ACTH) in humans. In vivo bioassay of corticotropin-releasing factor (CRF) which provides evidence for CRF mediation of the diurnal rhythm of ACTH.

Authors:  R A Salata; D B Jarrett; J G Verbalis; A G Robinson
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.